+

WO2002000241A3 - Compositions and methods for regulating the cell cycle using a ki gene or polypeptide - Google Patents

Compositions and methods for regulating the cell cycle using a ki gene or polypeptide Download PDF

Info

Publication number
WO2002000241A3
WO2002000241A3 PCT/EP2001/008096 EP0108096W WO0200241A3 WO 2002000241 A3 WO2002000241 A3 WO 2002000241A3 EP 0108096 W EP0108096 W EP 0108096W WO 0200241 A3 WO0200241 A3 WO 0200241A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
cell cycle
polypeptide
gene
Prior art date
Application number
PCT/EP2001/008096
Other languages
French (fr)
Other versions
WO2002000241A2 (en
Inventor
Didier Branellec
Elisabeth Lavenne
Roux Aude Le
Abderrahim Mahfoudi
Harris Perlman
Kenneth Walsh
Original Assignee
Aventis Pharma Sa
Saint Elizabeth S Medical Ct
Didier Branellec
Elisabeth Lavenne
Roux Aude Le
Abderrahim Mahfoudi
Harris Perlman
Kenneth Walsh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa, Saint Elizabeth S Medical Ct, Didier Branellec, Elisabeth Lavenne, Roux Aude Le, Abderrahim Mahfoudi, Harris Perlman, Kenneth Walsh filed Critical Aventis Pharma Sa
Priority to AU2001289652A priority Critical patent/AU2001289652A1/en
Publication of WO2002000241A2 publication Critical patent/WO2002000241A2/en
Publication of WO2002000241A3 publication Critical patent/WO2002000241A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention relates, generally, to compositions and methods for regulating the cell cycle, in particular apoptosis. The invention relates more specifically to compositions and methods using a Ki gene or polypeptide to regulate the cell cycle, in particular apoptosis, in cells, in vitro, ex vivo or in vivo. The invention also relates to compositions, vectors, cells and the like, which can be used to implement the above methods. This invention can be used to protect cells from apoptosis or to mediate or enhance apoptosis in cells, in various physio-pathological conditions.
PCT/EP2001/008096 2000-06-28 2001-06-22 Compositions and methods for regulating the cell cycle using a ki gene or polypeptide WO2002000241A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001289652A AU2001289652A1 (en) 2000-06-28 2001-06-22 Compositions and methods for regulating the cell cycle using a ki gene or polypeptide

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21479000P 2000-06-28 2000-06-28
US60/214,790 2000-06-28

Publications (2)

Publication Number Publication Date
WO2002000241A2 WO2002000241A2 (en) 2002-01-03
WO2002000241A3 true WO2002000241A3 (en) 2002-10-17

Family

ID=22800421

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/008096 WO2002000241A2 (en) 2000-06-28 2001-06-22 Compositions and methods for regulating the cell cycle using a ki gene or polypeptide

Country Status (2)

Country Link
AU (1) AU2001289652A1 (en)
WO (1) WO2002000241A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9560984B2 (en) 2009-10-29 2017-02-07 The Nielsen Company (Us), Llc Analysis of controlled and automatic attention for introduction of stimulus material

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2257152B1 (en) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. COMBINATIONS THAT INCLUDE ANTIMUSCARINIC AGENTS AND BETA-ADRENERGIC AGONISTS.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997016459A1 (en) * 1995-10-31 1997-05-09 Rhone-Poulenc Rorer S.A. Use of protein gax for treating cancer
WO1998017686A1 (en) * 1996-10-18 1998-04-30 Rhone-Poulenc Rorer S.A. Polypeptides comprising gax protein domains, involved in repressing transcription and/or interacting with other proteins, corresponding nucleic acids and their use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997016459A1 (en) * 1995-10-31 1997-05-09 Rhone-Poulenc Rorer S.A. Use of protein gax for treating cancer
WO1998017686A1 (en) * 1996-10-18 1998-04-30 Rhone-Poulenc Rorer S.A. Polypeptides comprising gax protein domains, involved in repressing transcription and/or interacting with other proteins, corresponding nucleic acids and their use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CIRCULATION, (1996) VOL. 94, NO. 8 SUPPL., PP. I472. MEETING INFO.: 69TH SCIENTIFIC SESSIONS OF THE AMERICAN HEART ASSOCIATION NEW ORLEANS, LOUISIANA, USA NOVEMBER 10-13, 1996 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; MAHFOUDI, ABDERRAHIM (1) ET AL: "Identification of a repressor domain in the growth arrest homeobox gene (GAX) that interacts with the nuclear antigen Ki.", XP002034391, retrieved from STN *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9560984B2 (en) 2009-10-29 2017-02-07 The Nielsen Company (Us), Llc Analysis of controlled and automatic attention for introduction of stimulus material

Also Published As

Publication number Publication date
AU2001289652A1 (en) 2002-01-08
WO2002000241A2 (en) 2002-01-03

Similar Documents

Publication Publication Date Title
WO2004044158A3 (en) Human embryonic stem cell cultures, and compositions and methods for growing same
WO2004029219A3 (en) Cell-based rna interference and related methods and compositions
AU2003216058A8 (en) Mammalian neural stem cells, compositions and uses thereof
NZ712789A (en) Placental stem cell populations
WO2006026570A8 (en) Use of stem cells to generate inner ear cells
IL152106A0 (en) Embryonic stem cells, neural progenitor cells derived therefrom and methods for the preparation thereof
WO2000053724A3 (en) Compositions and methods for the modification of gene transcription
HK1034999A1 (en) Dsrna-mediated regulation of gene expression in plants.
WO2001021766A8 (en) Methods and devices for obtaining non-hematopoietic lineage cells from hematopoietic progenitor cells
AU2002319780A1 (en) Alternative compositions and methods for the culture of stem cells
AU2002301347A1 (en) Embryonic stem cells and neural progenitor cells derived therefrom
WO2003027247A3 (en) Modulation of stem cells using zinc finger proteins
WO2007044083A3 (en) Evolved interferon-alpha polypeptides
WO2004046365A3 (en) Interferon-alpha polypeptides and conjugates
MXPA02003232A (en) Compositions and methods for altering gene expression.
WO2001004282A3 (en) Replication-competent anti-cancer vectors
DE602005002430D1 (en) cell line
WO2002060914A3 (en) Identification of small rnas and orfs form e. coli as mediators of cell and intercell regulation
WO2001049721A3 (en) Bacterial genes and proteins that are essential for cell viability and their uses
WO2004044127A3 (en) Stem cell populations
WO2005054439A3 (en) Small interfering rna (sirna)-mediated heritable gene manipulation in plants
WO2002055658A3 (en) Identification and characterization of an anthocyanin mutant (ant1) in tomato
WO2002000241A3 (en) Compositions and methods for regulating the cell cycle using a ki gene or polypeptide
AU8371501A (en) Manipulation of plant senescence using an MYB gene promoter and cytokinin biosyntyhesis genes
WO2002086112A3 (en) Nucleic acid molecules encoding starch degrading enzymes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载